NYSE:JNJ 2 December 2025 - 16 December 2025

Johnson & Johnson shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ closed at $214.17 and traded around $214.99 in after-hours as of 7:15 p.m. ET. During the regular session, the stock moved between $209.01 and $215.19 on roughly 8.4 million shares. StockAnalysis+1

Published: December 12, 2025 Johnson & Johnson stock is ending the week in the spotlight as shares hover near record territory, helped by a steady stream of analyst target updates, fresh late-stage clinical data disclosures, and a clearer roadmap for portfolio reshaping heading into 2026.

Johnson & Johnson closed regular trading on Thursday, December 11, 2025 at $210.01, up about 1.7% on the day, marking a fresh 52‑week high before easing slightly in after‑hours trading around $209.25. MarketScreener+1 That move capped a week of bullish Wall Street calls, powerful oncology data out of the ASH 2025 hematology meeting, and renewed focus on the company’s dealmaking and ongoing legal overhangs. Here’s what happened after the bell on December 11 – and what traders and longer‑term investors should watch heading into the December 12, 2025 U.S. market open.

Johnson & Johnson stock has gone from sleepy blue chip to market star in 2025. As of the morning of December 11, 2025, JNJ trades around $208 per share, sits at an estimated $500+ billion market capitalization, and is at its 52‑week high after a powerful rally that has outpaced the S&P 500. StockAnalysis+1 Since November 21, 2025, the story around Johnson & Johnson has been driven by three big themes:

Published: December 7, 2025 – ahead of Monday’s U.S. market open Johnson & Johnson heads into Monday’s session sitting just below its 52‑week high, with fresh drug data, new access to the Chinese market and ongoing talc litigation all pulling on the share price at once.

Johnson & Johnson heads into December 2025 as one of the market’s standout large‑cap healthcare performers, combining a 2025 share‑price surge with classic “defensive” traits like steady earnings and a long dividend track record—while still carrying a very real legal overhang from talc litigation. As of the close on Friday, December 5, 2025, JNJ shares finished at $201.93, near their record territory and not far below a recent 52‑week high around $207.81. Over the past 12 months the stock has climbed roughly 35%, with some measures putting its 2025 year‑to‑date total return close to 40%, far ahead of its sluggish performance in 2022–2023. Investing.com+2Investing.com+2